New 6-year data for Roche’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis

Ads

You May Also Like

ASTRAZENECA ANNOUNCES INVESTMENT IN MODERNA

This announcement contains inside information 10 August 2016 14:35 ASTRAZENECA ANNOUNCES INVESTMENT IN MODERNA ...

Aquinox to Present at LEERINK Partners 5th Annual Global Healthcare Conference

VANCOUVER, British Columbia, Jan. 28, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), ...